

Supplementary Table S5. *TP53*, *BRCA* and *PIK3CA* mutations in high-grade serous ovarian carcinoma ascitic fluid samples (n = 39)

S. No.	<i>TP53</i> amino acid change	<i>BRCA2</i> amino acid change	<i>BRCA1</i> amino acid change	<i>PIK3CA</i> amino acid change
1	Y220C	WT	WT	WT
2	Y220C	WT	WT	WT
3	F328Sfs*17	WT	WT	WT
4	I195T	WT	WT	WT
5	D228Efs*11	WT	WT	WT
6	Q167*	WT	WT	WT
7	H193Lfs*54	WT	WT	WT
8	G302Afs*47	WT	Q780*	E545Q
9	Q136*	WT	L598*	WT
10	C176G	WT	L1089*	WT
11	G112D	WT	WT	WT
12	R337C	WT	WT	WT
13	S127F	WT	S1480Cfs*26	WT
14	S376Ifs*6 N29T H178Pfs*70	WT	WT	WT
15	G112D	WT	WT	WT
16	WT	WT	WT	WT
17	T150Hfs*20 Q192*	WT	WT	WT
18	Q192*	WT	E111_N112insK*	WT
19	Y220C	WT	WT	WT
20	D228Efs*11	WT	WT	WT
21	R273H	WT	E23Rfs*18	WT
22	H193Lfs*54	WT	WT	WT
23	R290C	WT	WT	WT
24	S241Ifs*23; Q331* Q136*	WT	WT	WT
25	I255F	WT	L598*	WT
26	V173L	Q175*	WT	WT
27	V173L	Q175*	WT	WT
28	Q331*	WT	WT	WT
29	Q136*	WT	WT	WT
30	I255F	WT	L598*	WT
31	G112D	E1646*	WT	WT
32	Y220C	WT	WT	WT
33	R175H	WT	WT	WT
34	I195T	WT	WT	WT
35	Q317*	WT	WT	WT
36	Q192*	WT	Q780*	E545Q
37	Q192*	WT	Q780*	E545Q

38	Q192*	WT	Q780*	E545Q
39	A161T	WT	WT	WT

One case showed no detectable alteration in *TP53*, *BRCA1/2*, or *PIK3CA* and was considered molecularly non-informative for *BRCA*-stratified immune analysis.